Form 4 for PHAT Phathom Pharmaceuticals, Inc.
Accepted 2025-03-03 00:00:00 ET · period of report 2025-02-27 · accession 0000950170-25-031034 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-03 | 2025-02-27 | PHAT | Nabulsi Azmi | COO | A - Grant | $0.00 | +79.2K | 312.6K | +34% | $0 |
| D | 2025-03-03 | 2025-02-27 | PHAT | Nabulsi Azmi | COO | A - Grant | $0.00 | +55.0K | 55.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-27 | A | A | 79,200 | $0.00 | 312,590 | D | — | — | (F1) Represents restricted stock units ("RSUs") granted on February 27, 2025. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2025, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-02-27 | A | A | 55,000 | $0.00 | 55,000 | D | $5.76 · — to 2035-02-26 | 55,000 Common Stock | (F2) The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. |